Burdick Kenneth A sold $5.2M of CNC

Burdick Kenneth A sold 80,000 shares of CENTENE CORP (CNC) at $64.55 ($5.16M total) on 2026-06-10.

Original reporting
SEC EDGAR · Burdick Kenneth A
Published Jun 11, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CNC
Bearish
medium confidence
Mentioned
$CNC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNCBearishLow
01

Why it matters

The only new information is the disclosed sale size, price, and post-transaction holdings; it may slightly affect sentiment but lacks fundamental triggers.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing.

03

What to watch

No 10b5-1 plan is stated, but the filing alone cannot distinguish discretionary selling from scheduled personal liquidity needs; traders should check for repeated insider activity around the same period.

Relevance 6/10Novelty 6/10Timing: New SEC Form 4 filed June 11; sale executed June 10

Background

The article is an SEC Form 4 insider transaction disclosure for Centene’s director Kenneth A. Burdick.

Company-level read

Ticker impact

$CNCBearishMedium confidence
Context

Centene director Kenneth A. Burdick sold 80,000 shares in an open-market transaction worth about $5.164M, per a new SEC Form 4 filing.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not indicate company-specific deterioration (no earnings, guidance, or regulatory action) and notes no 10b5-1 plan.

Market effects

Minimal; single-insider sale does not reset sector fundamentals.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity/portfolio rebalancing and may not reflect forward-looking views, especially without evidence of a broader pattern.

Key entities

  • CENTENE CORP

    Subject of the SEC Form 4 insider transaction disclosure.

  • Burdick Kenneth A

    Director who sold 80,000 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$CVSMed

11 Medicare Advantage Insurers Sue CMS Over 2027 Star Ratings and Nearly $4 Billion in Payments

Eleven Medicare Advantage insurers, including CVS Health, Elevance Health, and Centene, sued the CMS over 2027 star ratings, claiming nearly $4 billion in potential losses. They argue CMS used unauthorized measures, citing a recent court ruling in Clover Health's favor. Higher ratings affect bonus payments and rebates. CMS is appealing the Clover decision and has not commented on the new lawsuits.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

High

Centene Surges 10.5% After Truist Securities Reiterates Buy

Centene Corporation's stock surged 10.5% to $74.56 on Wednesday, with a market cap of $37.3B, after Truist Securities, Wells Fargo, and JP Morgan raised their price targets by an average of 7.4%. Truist maintained a Buy rating, while Wells Fargo and JP Morgan adjusted their targets to $75 with Equal-Weight and Neutral ratings, respectively. The average price target is now $77, indicating potential upside.